Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment
Year: 2024
Type: article
Study design: Case Report
Abstract: This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease. It highlights the long-term effectiveness of C5 inhibitors in a real-world setting, aiding physicians in their decision-making for refractory cases and treatment discontinuation scenarios.
Source: Clinical Case Reports
DOI: 10.1002/ccr3.9547
Author: Stefan Quasthoff
Institution: Medical University of Graz
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,730
Funder: Alexion Pharmaceuticals
OpenAlex ID: W4404086729